Leeds

ECMC Leeds

Leeds ECMC draws on the scientific framework from four Yorkshire universities (Leeds, Bradford, Hull and York) with the aim of developing of new ways of treating and monitoring cancer. The Centre has wide experience of first-in-man and proof-of-principle early clinical trials of small molecules and biotherapies, both as single agents and in combination. Developing prognostic and predictive cancer biomarkers is another focus area.

Research Areas

Focus

Early clinical trials of small molecules and biotherapy, molecular and cellular pathology, proteomics and biomarkers, GCLP pharmacokinetics and pharmacodynamics (with Bradford), state-of-the-art MRI research (with Hull) and gene therapy (with York).

Disease Area

All types of cancer, especially bladder cancer, gastrointestinal cancer and prostate cancer.

 

Goals

Goals

For further information on the goals and objectives of Leeds ECMC go to:

More about Goals

 

Skills

Skills

Leeds ECMC principal investigators and staff have a diverse range of skills and expertise.

More about Skills

 

Facilities

Facilities

Leeds ECMC has access to a range of research facilities that are utilised in studies.

More about Facilities

 

Achievements

Achievements

To learn more about the scientific and operational achievements of Leeds ECMC go to:

More Achievements

 

Centre Leads

Professor Peter Selby
Leeds Institute of Molecular Medicine
Section of Oncology and Clinical Research
Cancer Research Building
St James's University Hospital
Beckett Street
Leeds
LS9 7TF
Tel: +44 (0) 113 206 5668

Professor Chris Twelves
Tel: +44 (0) 113 206 6949

Professor Roz Banks
Tel: +44 (0) 113 206 7469

Professor Phil Quirke
Tel: +44 (0) 113 343 8407

 

Other Key Personnel

Wendy Kennedy
Business Manager
Tel: +44 (0)113 206 4919

You can also find out about trials recruiting in Leeds on the CancerHelp UK clinical trials database.